Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 6/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1906114 | 0.81 | CYP1A2 (0.47) | KMT2ASMN1; SMN2ALDH1A1NPC1S1PR4 | |
| SCHEMBL4909016 | 0.81 | RAB9A (0.43) | KMT2ASMN1; SMN2ALDH1A1NPC1MAPT | |
| SCHEMBL1906253 | 0.78 | ALDH1A1 (0.40) | KMT2ASMN1; SMN2ALDH1A1NPC1HTT | |
| SCHEMBL316519 | 0.77 | RAB9A (0.41) | KMT2ASMN1; SMN2ALDH1A1NPC1S1PR4 | |
| SCHEMBL16927664 | 0.77 | PTGS2 (0.47) | KMT2ASMN1; SMN2ALDH1A1NPC1S1PR4 | |
| SCHEMBL1907231 | 0.75 | CYP2C9 (0.40) | SMN1; SMN2ALDH1A1NPC1S1PR4MAPT | |
| SCHEMBL3244643 | 0.70 | CYP2C9 (0.52) | KMT2ASMN1; SMN2ALDH1A1NPC1S1PR4 | |
| SCHEMBL12991623 | 0.69 | NPC1 (0.51) | KMT2ASMN1; SMN2ALDH1A1NPC1S1PR4 | |
| Bromide SCHEMBL11376966 | 0.68 | XDH (0.47) | KMT2ASMN1; SMN2ALDH1A1NPC1S1PR4 | |
| SCHEMBL1908255 | 0.68 | NPC1 (0.49) | KMT2AALDH1A1NPC1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197280-B1 | PYRAZOLE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2013-06-19 | — | — | EP | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1330442-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2011-01-19 | — | — | EP | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7750006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-7151102-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-12-19 | — | — | US | disclosed |
| US-20060142293-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1330442-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-12-05 | — | — | US | disclosed |
| WO-2002036576-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142293-A1 | Phthalazinone derivatives | CBR1, CBR3, PARP2 | KMT2A 1242/4885SMN1; SMN2 1094/4885ALDH1A1 466/4885 |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | PARP1, PARP11, PARP3 | KMT2A 589/4885SMN1; SMN2 501/4885ALDH1A1 208/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | KMT2A 1134/4885SMN1; SMN2 4519/4885ALDH1A1 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.